Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer

C N Sternberg, H Dumez, H Van Poppel, I Skoneczna, A Sella, G Daugaard, T Gil, J Graham, P Carpentier, F Calabro, L Collette, D Lacombe, EORTC Genitourinary Tract Cancer Group

109 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Docetaxel plus oblimersen sodium (Bcl-2 antisense oligonucleotide): an EORTC multicenter, randomized phase II study in patients with castration-resistant prostate cancer'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science